Spanish biotech company Zeltia (ZEL.MC: Quote, Profile, Research) said on Thursday European regulators rejected its appeal of a decision denying marketing approval for Yondelis, an anti-cancer drug it is developing with Johnson & Johnson (JNJ.N: Quote, Profile, Research) .
